Accelerate to discover

Back to filter

Related topics

IncuCyte webinar: high throughput approach to developing T- Cell immunotherapies

Sartorius

Jun 17, 2019

Immunotherapy for cancers involves artificially prompting the immune system to treat cancer. Many cancer cells have...

Low-dose imaging in a new preclinical total-body PET/CT scanner

Bruker Biospin

Jun 12, 2019

Ionizing radiation constitutes a health risk to imaging scientists and study animals. Both PET and CT produce ionizing...

Fluxion Biosciences and National Cancer Institute cooperate to validate IsoFlux for sequencing

Fluxion Biosciences

Jun 12, 2019

Fluxion with IsoFlux has partnered with the Cleveland Clinic. They are aiming to improve sensitivity by timing the...

New insight into Cas9 off-target activity

LUMICKS

Jun 7, 2019

Scientists at the MRC London Institute of Medical Sciences and AstraZeneca studied how CRISPR-Cas9 differentiates...

Jun 18, 2019

IncuCyte virtual event: Dimension of time - from culture to assay

Sartorius

Jun 5, 2019

This event offers an overview of how live-cell analysis enables real-time analysis for the full workflow of the cells....

Join the AVANCE Track & Keep your MRI on Track

Bruker Biospin

Jun 4, 2019

Your research depends on the scientific advances that you make with your MRI instrument. Take your instrument and your...

A novel method for isolating high-quality UHMW DNA from animal and human tissues

BioNano Genomics

May 31, 2019

New isolation protocol for isolating high-quality UHMW DNA from 10 mg of freshly frozen or liquid-preserved animal and...

Jun 18, 2019

From incubation to publication with IncuCyte S3 live-cell imaging system

Sartorius

May 29, 2019

Over 2000 peer-reviewed publications worldwide and growing. Explore the IncuCyte publications library, an up-to-date...

Show all topics (10)

Simultaneous non-invasive in vivo imaging of apoptosis and angiogenesis in a mouse model

Oct 20, 2016

Baseline angiogenesis and apoptotic activities were simultaneous evaluated before initiation of the treatment (D0) using the Bruker In-Vivo Xtreme imaging system, after i.p. administration of Angiosense680 EX and Annexin750 probes, respectively, according to the instructions of the supplier. After 3 days of treatment (D3), angiogenesis and apoptotic activities were similarly assessed; GLPG1790, Flavopiridol or Bevacizumab treatments were given 2hr prior to imaging.
All images were captured by a cooled CCD camera with the following parameters: f-stop 1.1, binning 2, 2 sec acquisition time for Angiosense680 EX and 5 sec acquisition time for Annexin750.
For anatomical co-registration, a reflectance image (0.1 second acquisition time, f-stop 2.8, binning 1) and an X-ray image (1.2 second acquisition time, f-stop 4, 45 KVP energy, 2 mm filter) were performed.
For precise co-registration, all images were taken with a 190 mm field of view (FOV). For each mouse and each probe, results were expressed as the difference between Net intensity at D3 and D0.

Read more

Scientific paper
Technical breakthrough
Application

Get more info

Miroslav Vecheta

Support specialist

Miroslav

Vecheta

+420 255 700 886

Send Message

Brand profile

Bruker Biospin

Bruker is a performace leader in preclinical imaging instrumentation. Bruker offers nine imaging modalities: PET, SPECT, CT, MRI, MPI, fluorescence, luminiscence, radioisotipic imaging and X-ray.

We supply and support Life-Science Technologies in the territory of Central and Eastern Europe.

Czech Republic

Slovakia

Hungary

Poland

Croatia

Slovenia

Serbia

Romania

Bulgaria

Latvia

Lithuania

Estonia

Russia

Ukraine

Belarus

Turkey